Independence Investment Fund Act
HB6412, the Independence Investment Fund Act, would create a new entity in the Department of the Treasury called the Independence Investment Fund to invest in U.S.-headquartered companies developing critical and emerging technologies. The bill’s stated goals are to strengthen national security and economic security, attract private capital into strategic sectors, provide an alternative source of financing for companies vulnerable to foreign or adversarial investment, and give the federal government better visibility into technology market trends. Biotechnology is specifically identified as a priority area, and the bill authorizes seed-to-mid-stage equity investments, with an average target investment size between $1 million and $10 million.
The bill sets up a governance structure with an initial advisory board that recommends the Fund’s roadmap, operating rules, and implementation details, followed by a standing supervisory board that must approve investments. The Secretary of the Treasury would oversee strategy in consultation with the Secretaries of Defense and Commerce, and would select an independent managing entity through an open competition to run the Fund. The managing entity would be expected to use venture-capital-style practices, provide technical assistance to portfolio companies, and report regularly on finances and progress. The bill also allows some investments or partnerships outside the United States, so long as they do not involve foreign entities of concern, and includes restrictions tied to CFIUS-related concerns and foreign investment exposure.
If enacted, the bill would add a new federal investment mechanism and associated reporting, oversight, and staffing authorities, while expressly exempting certain actions from the Administrative Procedure Act and the Paperwork Reduction Act. It authorizes nearly $1 billion for investment capital in fiscal year 2025, including $300 million for biotechnology, plus separate administrative funding and a conditional future appropriation trigger if biotechnology cash balances fall below a set threshold. The Fund itself would not be treated as a federal agency, department, or instrumentality, which may affect how it operates and what legal requirements apply.
Because there are no committee transcripts or recorded votes in the provided context, there is no documented floor or committee sentiment to assess beyond the bill’s bipartisan introduction by members from both parties. On its face, the bill appears oriented toward innovation, industrial policy, and national security, suggesting generally favorable interest among sponsors in using public capital to support strategic technologies. The absence of recorded opposition or amendments in the provided materials means there is no clear evidence of controversy in the available record.
Potential points of contention, based on the text alone, include the size of the proposed federal investment commitment, the use of a quasi-independent fund outside normal agency structures, and the degree of discretion given to Treasury and the managing entity. The bill’s exemptions from APA and paperwork requirements, its limited applicability of FACA to the advisory and supervisory boards, and its restrictions on foreign investment and intellectual property handling could also draw scrutiny from lawmakers concerned about transparency, accountability, or government involvement in private markets.
The bill would create a new Treasury-based investment fund and authorize substantial federal appropriations to finance equity investments in critical and emerging technology companies, especially biotechnology. It would establish new statutory definitions, governance boards, reporting obligations, staffing authorities, and procurement/transaction flexibilities, while also exempting certain actions from the Administrative Procedure Act and the Paperwork Reduction Act. The measure would affect Treasury, Defense, Commerce, CFIUS-related processes, and private technology firms seeking capital, and it would impose conditions on portfolio companies and the managing entity regarding foreign investment, reporting, and oversight.
The available context suggests generally supportive or at least constructive sentiment, since the bill was introduced with bipartisan cosponsors and there are no recorded votes or hearing transcripts indicating opposition. The bill’s framing emphasizes national security, economic security, and support for U.S. innovation, which are likely intended to appeal across party lines. However, without committee debate or vote data, the level of enthusiasm or concern among members cannot be measured from the provided record.
The main likely points of contention are the scale and structure of the federal investment program, the decision to house it in Treasury while using an independent managing entity, and the bill’s reduced exposure to ordinary administrative-law procedures. Members concerned about government picking winners and losers may question direct equity investments in private companies, while others may focus on the foreign-entity restrictions, CFIUS-related provisions, and the possibility of government influence over company governance and intellectual property. Transparency, conflicts of interest, and oversight of the advisory and supervisory boards are also likely areas of concern, especially given the bill’s exemptions from FACA and other procedural statutes.